MiMedx Group (MDXG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

MiMedx Group

NasdaqCM•Healthcare•Biotechnology

$4.69-0.04(-0.01%)Pre-market

Market Cap

$693.16M

P/E

111.1x

P/S

2.0x

P/B

3.2x

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.

How this company scores

AverageMetricSide Score: 45/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Profitability (4/25).

Profitability4/25

Growth7/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality15/25

Strengths

Low leverageCash-backed earningsNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 111.1x5y range 9.8x – 195.5x

Currently above its 12-quarter median.

P/S · 2.0x5y range 1.2x – 4.0x

Currently near its 20-quarter median.

P/B · 3.2x5y range 2.4x – 8109.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 139.4% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Price & Volume

Market Cap $693.16M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $355.17M
Q. Revenue: $64.36M
TTM EBITDA: $24.99M
TTM Op. Income: $8.75M
Q. Op. Income: $-18.47M
TTM Net Income: $6.24M
Q. Net Income: $-14.84M
EPS: $-0.1
Shares Out.: $147.80M

$355.17M in TTM revenue declined 2.4% YoY, reaching $64.36M last quarter. TTM EBITDA of $24.99M and TTM operating income of $8.75M show growth is flowing through to the bottom line. TTM net income of $6.24M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 69.0%
EBITDA Margin: -28.3%
Op. Margin: -28.7%
Net Margin: -23.1%

Op. margin of -28.7% is down 41.2% YoY — costs are rising relative to revenue. Net margin at -23.1% and gross margin of 69.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 111.1x
P/S Ratio: 2.0x
P/B Ratio: 3.2x

At 111.1x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 2.0x and P/B of 3.2x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 296% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $281.00M
Cash: $135.84M
Long-Term Debt: $15.71M
Book Value: $216.00M
D/E Ratio: 0.1
Debt/EBITDA: N/A

With $281.00M in assets and $15.71M in long-term debt, D/E is 0.1and book value is $216.00M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-10.02M
TTM Free Cash Flow: $44.50M
FCF Margin: 12.5%
FCF / Net Income: 7.1

TTM FCF of $44.50M on $-10.02M in operating cash flow. The FCF / Net Income ratio of 7.1x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.